Genomma Lab Internacional SAB de CV

Genomma Lab Internacional SAB de CV

Health CarePharmaceuticals & Biotechnology
  • Price (MXN)19.47
  • Today's Change0.48 / 2.53%
  • Shares traded1.33m
  • 1 Year change43.69%
  • Beta--
Data delayed at least 20 minutes, as of Oct 22 2019.
More ▼

Events & Activity

  • LABB:MEX price reached a new 52-week high of 19.36 at 10:06 BST
  • LABB:MEX trading volume exceeds daily average by +29.77%
  • LABB:MEX price moved over +1.46% to 18.79
  • LABB:MEX price rises above 15-day moving average to 18.88 at 10:13 BST

Key statistics

Genomma Lab Internacional SAB de CV (LABB:MEX) set a new 52-week high during Tuesday's trading session when it reached 19.47. Over this period, the share price is up 47.61%.
52-week range
11.10Dec 17 201819.47Oct 22 2019
Markit short selling activity
Previous close18.99
Average volume1.48m
Shares outstanding1.05bn
Free float1.04bn
P/E (TTM)21.85
Market cap20.32bn MXN
EPS (TTM)0.8874
Data delayed at least 20 minutes, as of Oct 22 2019.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.